Casablanca – Moroccan pharmaceutical group Sothema has signed an agreement to acquire 100% of Ramo Pharm, a Casablanca-based company that develops and markets dietary supplements. The transaction remains subject to customary closing conditions, including authorization from Morocco’s Competition Council, Sothema said in a statement today.
Ramo Pharm began operating in 1999 and has built a portfolio of brands sold through Moroccan pharmacies. These include Enrouex, ZENmag, Toudex, Hivernex, CD Zinc and Matervit. Its products cover several areas, including ear, nose and throat care, immunity, stress and sleep, and women’s health. The company also has a pipeline of new products to support its future growth, according to Sothema.
The acquisition forms part of Sothema’s plan to organize its activities around four therapeutic areas. These include general medicine and chronic care, specialty products, dialysis solutions, and wellness and consumer health.
Sothema said the deal would strengthen its existing brand portfolio, speed up the development and launch of new products, and support international expansion through its distribution networks abroad. The companies also plan to draw on operational synergies to expand the business.
Chief Executive Lamia Tazi said the acquisition would lay the foundations for a platform that could accelerate the development of the two companies’ portfolios in Morocco and internationally. Ramo Pharm managing partner Karim Akouz described Sothema as the right partner to preserve the company’s approach, continue its growth and give the business a wider reach.
Read also: Morocco’s Pharmaceutical Trade Deficit to Reach $1.4 Billion by 2030
The deal comes after a strong first half for Sothema. The company reported consolidated revenue of MAD 1.8 billion ($182.3 million) in the first six months of 2026, up 16% from a year earlier. Net profit attributable to the group rose 11% to MAD 215 million ($21.8 million), according to its September financial results. Sothema also launched three products in Morocco during the period, including two in cardiology and one in oncology.
The announcement also follows a separate proposed acquisition in Morocco’s pharmaceutical sector. On October 22, the Competition Council published details of Laprophan’s proposed acquisition of exclusive control of Corporate Investment Holding and its subsidiaries.
The transaction involves markets for drugs and dietary supplements, and the council set November 2 as the deadline for interested third parties to submit observations. The case remains separate from Sothema’s agreement with Ramo Pharm.
Sothema began operating in 1976 and marks 50 years in business this year. The group manufactures and markets medicines, dietary supplements, and medical devices. It works with 50 pharmaceutical laboratories through licensing partnerships and sells its own generic and biosimilar products in Morocco, sub-Saharan Africa, and the Middle East.
